Genomictree Inc. (KOSDAQ:228760)

South Korea flag South Korea · Delayed Price · Currency is KRW
20,750
+700 (3.49%)
At close: Feb 27, 2026
Market Cap503.53B +19.3%
Revenue (ttm)3.76B +70.9%
Net Income-8.77B
EPS-366.23
Shares Out24.27M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume290,175
Average Volume210,923
Open20,150
Previous Close20,050
Day's Range19,910 - 21,750
52-Week Range11,390 - 33,300
Beta0.13
RSI40.29
Earnings DateMar 18, 2026

About Genomictree

Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect C, a screening method for early diagnosis of colorectal cancer; EarlyTect L for detection of epigenetic markers associated with lung cancer in pulmonary nodule patients; and EarlyTect B for detection of genetic and epigenetic markers associated with bladder cancer in hematuria patients. It also provides AccuraDTect SARS-CoV-2 RT-qPCR... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 228760
Full Company Profile

Financial Performance

In 2024, Genomictree's revenue was 2.36 billion, a decrease of -30.89% compared to the previous year's 3.42 billion. Losses were -10.24 billion, 17.0% more than in 2023.

Financial Statements